Proventil


Also found in: Dictionary, Thesaurus, Wikipedia.

Proventil

 [pro-ven´til]
trademark for preparations of albuterol, a bronchodilator.

Proventil

(prō-vĕn′tl, prō′vĕn′tl)
A trademark for the drug albuterol.

Proventil

a trademark for a bronchodilator (albuterol).

Proventil®

Critical care An albuterol sulfate-based metered dose inhaler–MDI used to relieve asthma attacks. See Asthma.

Patient discussion about Proventil

Q. Is a Proventil Inhaler cheaper by you than Secirity Blue? I pay $60. with Security Blue now. Is it cheaper with you for a three months supply ?

A. here is a drug prices comparing site-
http://www.compare-prescription-prices.com/drug/Proventil.htm

but i couldn't find there that other drug you were talking about....is that it's name?

More discussions about Proventil
References in periodicals archive ?
Her medications were proventil and azmacort, given by her PCP for what was believed to be new-onset asthma.
For people who have mild or infrequent attacks, inhalers containing bronchodilators (such as Proventil, Ventolin, Alupent, and Metaprel) are widely prescribed and have proved in most cases to be very useful.
Respiratory products include PROVENTIL HFA, the first HFA-propelled albuterol MDI, and the first non-sedating antihistamine CLARITIN (loratadine).
REDDY'S LABORATORIES 203 SUN PHARMA 203 SANDOZ 204 TEVA 205 CHAPTER 10 PATENT ANALYSIS 208 PATENT LANDSCAPE AND EFFECT ON SPENDING 208 TABLE 76 COPD KEY FACTS AND CHALLENGES 209 LATEST NEWS 210 ASTRAZENECA 210 REGULATORY ISSUES 210 NEW PATENT FILINGS 211 COMPETITIVE LANDSCAPE 212 TABLE 77 AREAS FOR DRUG DELIVERY IMPROVEMENTS 212 KEY PATENTS 213 Advair and Patent Issues 213 TABLE 78 PULMONARY DRUG DELIVERY TECHNOLOGIES AND KEY PATENTS 213 Proventil HFA 214 KEY FACTS 215 CONCLUSION 215 CHAPTER 11 REFERENCES 218
The more widely used maintenance drugs with reduced co-pays include: Avapro and Benicar, both used to treat hypertension; Actos and Lantus, used to treat diabetes; Symbicort, used to treat COPD; and Proventil HFA, for COPD and asthma.
Scenario 1: Proventil HFA Takes Early Market Leadership
Sales of Short-Acting Beta2 Agonists (Scenario 1: Proventil Takes Early Market Leadership), 2006-2011
In the study, the overall incidence of adverse events in the XOPENEX HFA (72%) and PROVENTIL HFA (76.